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We analyzed the genes expressed (transcriptomes) and the proteins translated (pro-
teomes) in muscle tissues and activated CD4+ and CD8+ T-lymphocytes (T-cells)
of f ive Type 2 diabetes (T2DM) subjects using Affymetrix microarrays and mass
spectrometry, and compared them with matched non-diabetic controls. Gene ex-
pressions of insulin receptor (INSR), vitamin D receptor, insulin degrading enzyme,
Akt, insulin receptor substrate-1 (IRS-1), IRS-2, glucose transporter 4 (GLUT4),
and enzymes of the glycolytic pathway were decreased at least 50% in T2DM than
in controls. However, there was greater than two-fold gene upregulation of plasma
cell glycoprotein-1, tumor necrosis factor α (TNFα), and gluconeogenic enzymes
in T2DM than in controls. The gene silencing for INSR or TNFα resulted in the
inhibition or stimulation of GLUT4, respectively. Proteome profiles correspond-
ing to molecular weights of the above translated transcriptomes showed different
patterns of changes between T2DM and controls. Meanwhile, changes in tran-
scriptomes and proteomes between muscle and activated T-cells of T2DM were
comparable. Activated T-cells, analogous to muscle cells, expressed insulin sig-
naling and glucose metabolism genes and gene products. In conclusion, T-cells
and muscle in T2DM exhibited differences in expression of certain genes and gene
products relative to non-diabetic controls. These alterations in transcriptomes and
proteomes in T2DM may be involved in insulin resistance.
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Introduction
T-lymphocytes (T-cells) are unique in that in the
native resting state they do not possess insulin re-
ceptors (INSRs) and are insulin insensitive; however,
within 24 hours after activation with phytohemagglu-
tinin (PHA), T-cells develop receptors for a variety
of growth factors such as insulin, insulin-like growth
factor 1 (IGF-1), and interleukin-2 (IL-2), which con-
tinue to increase in number up to 72 hours (1–5 ).
T-cells also develop certain enzymatic mechanisms
for the metabolism of various substrates concomitant
with the development of these receptors (4 , 5 ). Our
previous studies have demonstrated that insulin bind-
ing and responsiveness are reflective of the donor’s
glycemic status and ambient insulin levels (4 , 6 , 7 ),
and have shown that the activation of T-cells exhibits
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changes in certain transcriptomes and proteomes con-
sistent with metabolic changes noted with their acti-
vation (8 ).
With our studies of in vivo activation of T-cells,
we noted under hyperglycemic conditions (for exam-
ple, diabetic ketoacidosis) that there was in situ ac-
tivation with de novo emergence of growth factor re-
ceptors, such as receptors for insulin, IGF-1, and IL-2
(9 ). Our in vitro studies have demonstrated that the
level of activation is glucose concentration and time-
dependent (10 ). This activation is associated with
signs of oxidative stress, such as production of reac-
tive oxygen species (ROS), dichlorofluorescein, and
lipid peroxidation (as determined by thiobarbituric
acid) reactive molecules (11 ).
In insulin responsive tissues, insulin binds to its re-
ceptor and initiates insulin signal transduction path-
ways. However, cells of patients with Type 2 diabetes
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(T2DM) exhibit inhibition of post receptor events
and alteration of signal transduction pathways (12–
16 ). Since studies have demonstrated that insulin
signal transduction in skeletal muscle, which is an
insulin responsive tissue and a major tissue for glu-
cose metabolism, is affected by the level of glucose
to which the muscle is exposed (17 , 18 ), we carried
out genomic and proteomic analyses on muscle tis-
sues of normal and T2DM subjects. Additionally,
since our earlier studies on activated T-cells of nor-
mal subjects involving transcriptome and proteome
studies appear to be consistent with the changes in
muscle tissues (8 ), we hypothesize that the transcrip-
tomes and proteomes of activated T-cells of T2DM
subjects are different from those of normal subjects
and are parallel to those of muscle tissues.
Therefore, our aims in this study were: (1) to
analyze and compare the genes expressed (transcrip-
tomes) in muscle tissues and activated and non-
activated T-cells of normal and T2DM subjects, fo-
cusing predominantly on gene alterations in the area
of insulin signal transduction and glucose metabolic
pathways; and (2) to determine the proteins trans-
lated (proteomes) in muscle tissues and activated and
non-activated T-cells of normal and T2DM subjects.
Since CD4+ and CD8+ T-cells exhibit different
immunological properties but similar de novo emer-
gence of growth factor receptors (5 ), we studied ac-
tivated and non-activated CD4+ and CD8+ T-cells
in regard to alteration of gene expression using the
Affymetrix human genome microarray chips. We re-
port here significant changes in muscle tissues and
activated T-cells of T2DM subjects compared with
those of non-diabetic subjects in regard to expression
of transcriptomes and proteomes, which may be in-
volved in the insulin resistance of T2DM subjects. To
our knowledge, this is the first report of these phe-
nomena.
Results
Clinical and biochemical data
Table 1 summarizes the clinical and biochemical data
on five normal and five diabetic (T2DM) subjects.
The diabetic subjects had elevated fasting blood glu-
cose (FBG) and oral glucose tolerance test (OGTT)
values indicative of diabetes, as well as an elevated
HbA1c percentage. Based on the homeostasis model
assessment of insulin resistance (HOMA IR), the nor-
mal subjects were not insulin resistant, whereas the
diabetic subjects showed marked insulin resistance. It
should be noted that these normal male subjects were
in good physical condition and good muscle tone, and
the body mass index (BMI) is not a good indicator of
obesity as also indicated by HOMA IR.
Gene expression
The genes expressed in muscle tissues and activated
CD4+ and CD8+ T-cells in the five newly diagnosed
diabetic subjects were compared with those in the five
matched (age, gender, ethnicity, and BMI) normal
subjects, since neither of the non-activated CD4+ or
CD8+ T-cells showed any growth factor and insulin
signaling expression as we have previously reported
(8 ). Figure 1 shows the scatter map of genes increased
(red), unchanged (blue), and decreased (green) in ac-
tivated CD4+ T-cells between diabetic and normal
subjects. Much more genes were noted to be de-
creased in expression in diabetic subjects. Similar
relationships were also noted in activated CD8+ T-
Table 1 Clinical and biochemical characteristics of subjects studied
Parameter Normal subjects Diabetic subjects
No. of subjects 5 5
Age (year) 41.2±2.6 39.4±2.3
BMI (kg/m2) 32.4±2.0 34.5±2.4
Temperature (◦C) 37.0±0.08 37.0±0.09
HbA1c (%) 5.2±0.03 8.9±0.8
White blood cells (×106/cc) 5.9±0.6 6.3±0.5
FBG (mM) 5.0±0.2 10.5±1.0
Fasting insulin (pM) 41.4±2.4 171.6±14.4
HOMA IR 1.6±0.2 13.4±0.9
Cholesterol level (mg/dL) 162±14 254±33
Triglyceride level (mg/dL) 126±18 223±36
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Fig. 1 The scatter map of genes increased (red), un-
changed (blue), and decreased (green) in the activated
CD4+ T-cells of diabetic subjects compared with normal
subjects.
cells as well as muscle tissues between diabetic and
normal subjects (data not shown). The numerous
changes in these cells were grouped into gene ontolo-
gies (GOs). Table 2 lists the selected GOs and the
number of genes with decreased or increased expres-
sion in activated CD4+ T-cells of diabetic subjects
compared with those of normal subjects. Much more
genes were decreased in expression in these GOs of di-
abetic subjects, especially those for physiological pro-
cesses, cellular processes, and metabolism.
Figure 2 shows the hierarchial clustering heat map
of the genes expressed in activated CD4+ T-cells
of diabetic subjects in relationship to normal sub-
jects, which are involved in insulin signal transduc-
tion (Group 1), inflammation (Group 2), and carbo-
hydrate metabolism (Group 3). Most of the genes
involved in these pathways were decreased in diabetic
subjects. However, some of the genes were increased
in expression in diabetic subjects, including genes of
ectonucleotide pyrophosphatase/phosphodiesterase-1
(ENPP-1) or plasma cell glycoprotein-1 (PC-1),
Forkhead transcription factor 1 (Foxo1), phosphe-
nolpyruvate carboxykinase (PEPCK), fructose-1,6-
bisphophatase (FBP), carnitine acyl transferase
(CAT), and pyruvate dehydrogenase kinase (isoen-
zyme 4) (PDK4). Additionally, inflammatory genes
of tumor necrosis factor α (TNFα), TNFα receptor,
Table 2 Gene expression changes grouped by
ontologies
Gene ontology Decreased Increased
in T2DM in T2DM
Physiological processes 2,242 656
Cellular processes 1,562 368
Development 556 80
Metabolism 1,419 490
Cell growth and/or maintenance 830 262
Response to external stimulus 401 83
Response to stress 225 64
and nuclear factor kappa B (NFKB1) were also in-
creased in expression in diabetic subjects, while the
T-cell growth factor IL-2, IL-2 receptor (IL-2R), and
vitamin D receptor (VDR) were decreased in expres-
sion in diabetic subjects.
The differences of the growth factor receptor gene
expressions in muscle tissues and activated CD4+
and CD8+ T-cells were quantitatively compared be-
tween normal and diabetic subjects. The directions
of changes in gene expression were the same in these
patients; they were significantly lower in diabetic sub-
jects than in normal subjects as shown in Figure 3.
Table 3 summarizes the fluorescence intensities of
the microarray gene chips of some of the genes with
changed expression in muscle tissues and activated
CD4+ and CD8+ T-cells of normal and diabetic sub-
jects. Gene expressions of growth factor receptors and
enzymes of the glycolytic pathway as well as insulin
signal transduction were decreased at least 50% in
muscle tissues and activated T-cells of diabetic sub-
jects. In contrast, ENPP-1 (PC-1), associated with
diabetes and insulin resistance, was increased to at
least two folds in diabetic subjects. PEPCK, involved
in the gluconeogenic pathway, was also increased over
two folds in diabetic subjects. Significant changes
in enzymes involved in signal transduction pathways
were noted to be concomitant with the development
of insulin insensitivity in these tissues. Table 4 lists
the genes and their Unigene IDs that are shown in
the hierarchial clustering heat map of Figure 2. The
down arrow, up arrow, and horizontal arrow indicate
a decrease, increase, or no change, respectively, in the
gene expression in diabetic subjects compared with
that in normal subjects.
To confirm the gene expression results obtained by
the microarrays, quantitative reverse transcription-
polymerase chain reaction (RT-PCR) was performed
on some of the transcriptomes. Table 5 shows the
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Fig. 2 The hierarchical clustering heat map of genes involved in insulin signal transduction (Group 1), inflammation
(Group 2), and carbohydrate metabolism (Group 3) in activated CD4+ T-cells of diabetic and normal subjects. The
green color indicates the genes decreased in expression and the red color indicates the genes increased in expression.
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Fig. 3 The growth factor receptor transcriptomes in muscle tissues and activated CD4+ and CD8+ T-cells of normal
and diabetic subjects.
Geno. Prot. Bioinfo. Vol. 5 No. 3–4 2007 219
Gene and Protein Expressions in Muscle and T-Cells of T2DM
Table 3 Transcriptome levels in muscle tissues and CD4+ and CD8+ T-cells of normal and diabetic
subjects (mean±standard deviation of f luorescence intensities)
Transcriptome Muscle CD4+ CD8+
Normal Diabetic Normal Diabetic Normal Diabetic
INSR 1,270±40 416±34* 803±48 244±29* 760±44 212±26*
IGF-1R 1,626±52 485±43* 1,684±45 335±38* 1,719±49 381±31*
IL-2R 15±1 15±1 1,472±66 687±47* 873±56 412±36*
VDR 1,374±49 613±46* 2,834±51 846±42* 2,457±48 724±40*
IDE 1,760±58 734±51* 1,515±44 338±39* 1,382±46 296±35*
Akt 1,483±63 556±57* 1,384±76 435±48* 1,270±69 389±44*
IRS-1 1,940±65 810±55* 1,474±63 578±52* 1,328±67 631±56*
IRS-2 1,237±60 621±52* 1,314±68 652±58* 1,194±65 588±47*
HK 2,786±94 1,191±67* 2,254±91 964±67* 2,382±86 1,012±64*
PFK 3,634±71 872±58* 3,286±81 647±72* 2,974±74 583±58*
PDH 1,543±61 719±63* 1,062±76 453±49* 893±73 415±44*
ENPP-1 818±46 1,760±59* 764±51 1,657±60* 703±53 1,564±59*
GLUT4 1,286±67 591±52* 615±58 273±36* 562±57 241±34*
GAPD 2,858±84 1,406±79* 2,285±93 1,037±64* 1,974±90 964±61*
CALM 2,012±54 804±46* 1,647±44 715±47* 1,792±61 689±53*
PEPCK 685±42 2,033±57* 591±39 1,872±52* 495±38 1,708±59*
*Significant difference (p < 0.05) between normal and diabetic subjects. HK, hexokinase; PFK, phosphofructokinase;
PDH, pyruvate dehydrogenase; GAPD, glyceraldehyde-3-phosphate dehydrogensase; CALM, calmodulin.
Table 4 Identif ication of genes expressed in activated CD4+ T-cells of diabetic subjects
Gene ID Identification Expression
Hs.465744 Insulin receptor (INSR) ↓
Hs.500546 Insulin degrading enzyme (IDE) ↓
Hs.487062 Insulin-like growth factor-2 receptor (IGF-2R) ↓
Hs.20573 Insulin-like growth factor-1 receptor (IGF-1R) ↓
Hs.471508 Insulin receptor substrate-1 (IRS-1) ↓
Hs.442344 Insulin receptor substrate-2 (IRS-2) ↓
Hs.525622 Akt/Protein kinase B (PKB) ↓
Hs.15744 SH2-B homolog ↓
Hs.464971 Phosphoinositide-3-kinase (PI3K) ↓
Hs.104123 Phosphoribosyl pyrophosphate synthetase 3 ↓
Hs.123253 SHC SH2 domain binding protein 1 ↓
Hs.531704 Protein kinase C ↓
Hs.282410 Calmodulin ↓
Hs.513661 Mitogen act protein II ↓
Hs.203420 Tyrosine kinase I ↓
Hs.408312 Tumor protein p53 ↓
Hs.159161 Rho GDP dissociation inhibitor (GDI) ↓
Hs.505469 Rac (GTPase activating protein) ↓
Hs.518355 G-elongation factor (mito 1) ↓
Hs.369779 Sirtuin1 (SIRT1) ↓
Hs.397729 HMGCoA synthase (HMGCS1) ↔
Hs.103854 Dock protein 1 (downstream of tyrosine kinase 1) ↓
Hs.431850 MAP kinase (ERK) ↓
Hs.463642 Ribosomal protein kinase S6 ↓
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Table 4 Continued
Gene ID Identification Expression
Hs.431498 Foxo1 ↑
Hs.458285 SH3 domain (GRB3-like 2) ↓
Hs.487897 Phosphodiesterase (PDE1C) ↓
Hs.524461 SP1 ↓
Hs.162646 Peroxisome proliferative activated receptor γ ↓
Hs.527295 ENPP-1 ↑
Hs.413513 Inhibitor kinase (I kappa B) ↓
Hs.89679 Interleukin-2 (IL-2) ↓
Hs.231367 IL-2 receptor (IL-2R) ↓
Hs.401745 TNFα receptor 2 ↑
Hs.478275 TNFα ↑
Hs.524368 Vitamin D receptor (VDR) ↓
Hs.431926 Nuclear factor kappa B (NFKB1) ↑
Hs.466471 Glucose phosphate isomerase ↓
Hs.479728 Glyceraldehyde-3-phosphate dehydrogenase (GAPD) ↓
Hs.444422 Pyruvate dehydrogenase kinase (isoenzyme 4) (PDK4) ↑
Hs.513490 Aldolase A ↓
Hs.75160 Phosphofructokinase (PFK) ↓
Hs.464071 Phosphogluconate dehydrogenase ↓
Hs.171499 Diacylglycerol kinase ↓
Hs.131255 Ubiquinol-Cyto C reductase binding protein (UQCRB) ↓
Hs.61255 Fructose-1,6-biphosphatase 2 (FBP) ↑
Hs.2795 Lactate dehydrogenase A ↓
Hs.148266 Glycerol-3-phoshate dehydrogenase 2 (mito) ↓
Hs.546323 Succinate-CoA ligase (ADP forming B sub) ↓
Hs.12068 Carnitine acyl transferase (CAT) ↑
Hs.199776 Potassium inwardly rectifying channel, subfam 3–6 ↔
Hs.430606 Citrate synthase ↓
Hs.530274 Aldolase B, fructose-biphosphate ↓
Hs.517145 Enolase 1 ↓
Hs.413238 Phosphoglycerate mutase 1 ↓
Hs.154654 Cytochrome p450 family subunit B ↓
Hs.83765 Dihydrofolate reductase ↓
Hs.406266 Hexokinase-2 (HK) ↓
Hs.567249 Soluble carrier family 2 (fac glu trans) mem 4 (GLUT4) ↓
Hs.1872 Phosphoenolpyruvate carboxykinase (PEPCK) ↑
Hs.358935 Soluble carrier family 5 (Na/glu cotrans) mem 10 ↓
Hs.524219 Triosphosphate isomerase ↔
Hs.130036 Protein phosphatase 1 ↓
Hs.198281 Pyruvate kinase, cGMP dependent, type 1 ↓
Hs.151176 AcetylCoA carboxylase ↓
Hs.530331 Pyruvate dehydrogenase (PDH) ↓
gene expression comparison results of 23 genes se-
lected from the list of genes in Table 4. The mRNA
levels of normal subjects were compared with those of
diabetic subjects for the respective tissues using the
factor ∆∆Cttest gene. The larger the ∆∆Cttest gene,
the less the amount of mRNA in diabetic subject
cells than in normal subject cells. The negative val-
ues indicate increased expression of mRNA in diabetic
subjects than in normal subjects, which confirms the
increased expression of these genes (FBP, PEPCK,
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Table 5 Changes in gene expression determined by quantitative RT-PCR
Gene expression ∆∆Ct
Muscle CD4+ CD8+
GAPD 1.8 1.6 1.5
PFK 2.6 2.3 2.3
FBP −1.9 −1.8 −1.8
HK 1.9 1.7 1.6
GLUT4 1.5 1.5 1.5
PEPCK −2.5 −2.2 −2.2
Soluble carrier family 5 (Na/glu cotrans) mem 10 0.7 0.6 0.6
PDH 1.6 1.5 1.4
CAT −1.2 −1.1 −1.1
INSR 1.8 1.9 1.9
IDE 2.2 1.7 1.6
IGF-1 1.9 2.3 2.2
IRS-1 1.6 1.7 1.6
Akt 1.7 1.9 1.8
Calmodulin 1.6 1.5 1.5
PDK4 −1.3 −1.2 −1.2
Foxo1 −1.4 −1.3 −1.1
PDE1C 1.6 1.5 1.5
SP1 1.4 1.3 1.3
ENPP-1 −1.5 −1.4 −1.4
IL-2R 0 1.6 1.6
NFKB1 −1.4 −1.5 −1.6
VDR 1.7 2.3 2.1
18S rRNA – – –
CAT, PDK4, Foxo1, ENPP-1, and NFKB1) observed
with the Affymetrix microarrays in diabetic subjects.
Figure 4 shows the percent relative gene expression
determined when RNA interference (RNAi) was used
for gene knockout to study the effect of mRNA ex-
pression levels. The CD4+ T-cells of normal subjects
were transfected with Silencer siRNAs before activa-
tion of the cells, and the mRNA knockout levels were
measured. Using 1 nM and 10 nM concentrations of
INSR siRNAs resulted in a decrease and almost to-
tal knockout of the mRNA levels for INSR and glu-
cose transporter 4 (GLUT4), respectively. Using 1
nM and 10 nM concentrations of TNFα siRNAs re-
sulted in a decrease and almost total knockout of the
mRNA levels for TNFα, respectively, but an increase
in the mRNA levels for GLUT4 (data not shown). 18S
rRNA was used to normalize from sample to sample.
Proteomics analysis
To further evaluate the nature of the proteomic
changes, total cellular proteins from muscle tissues
and activated and non-activated CD4+ and CD8+ T-
cells of normal and diabetic subjects were analyzed us-
ing two-dimensional polyacrylamide gel electrophore-
sis (2D-PAGE) and mass spectrometry (MS). Figure 5
(A and B) shows the 2D gel profiles of activated CD4+
T-cells of diabetic and normal subjects, respectively,
with pI ranging from 3 to 10 for the first dimension.
This demonstrates the numerous changes in proteins
between diabetic and normal CD4+ T-cells. Numer-
ous differences between diabetic and normal CD8+
T-cells and muscle tissues were also observed (data
not shown).
Because of the large number of differences in pro-
tein spots on the 2D gels and the large number of sam-
ples to be analyzed in this study, the muscle tissues
and activated CD4+ and CD8+ T-cells of diabetic and
normal subjects were analyzed on a Beckman Coulter
ProteomeLab PF 2D Protein Fractional System (Fig-
ure 5C). The protein peaks were compared between
diabetic and normal subjects (Figure 5D). The col-
lected protein peaks were then subjected to further
analysis by matrix-assisted laser desorption/ionization
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Fig. 4 The effect of gene silencing of mRNAs for INSR and GLUT4 using siRNAs for INSR.
time-of-flight (MALDI-TOF) MS.
Figure 6 (A and B) shows the mass spectro-
metric profiles in the m/z range of 100–30,000 and
30,000–150,000, respectively, using the gold metal
microarrays on a Ciphergen PBSII surface-enhanced
laser desorption/ionization time-of-flight (SELDI-
TOF) mass spectrometer with Ciphergen ProteinChip
3.1 and Biomarker Wizard software. As can be seen
from the figure, there are numerous differences in pro-
tein patterns of activated T-cells between normal and
diabetic subjects. These differences appear to cor-
relate with the numerous differences observed in the
transcriptomes of activated and non-activated T-cells
between normal and diabetic subjects as well as in
the proteins observed with 2D-PAGE. It is proposed
that some of these proteins may serve as biomark-
ers in T2DM during their cell activation. Table 6
shows some of these possible biomarkers for the acti-
vation of CD4+ T-cells and muscle tissues for T2DM
in the m/z range of 500–150,000, which were deter-
mined from the MS peak map data analysis of the
triplicate samples of normal and diabetic subjects.
Proteins with these m/z values were determined to
be either unique or were increased or decreased sig-
nificantly in concentration in activated CD4+ T-cells
or muscle tissues of diabetic subjects compared with
those of normal subjects. For example, the peak in-
tensity of the m/z value of 119,700 was decreased in
CD4+ T-cells and muscle tissues of diabetic subjects.
This m/z value may correspond to the insulin degrad-
ing enzyme (IDE) since its transcriptome was deter-
mined to be decreased in expression in diabetic sub-
jects. On the other hand, the peak intensity of the
m/z value of 110,000 was increased in diabetic sub-
jects; the m/z values of 15,642, 16,721, and 17,356
were present in diabetic subjects but not in normal
subjects; and the peak intensity of the m/z value of
21,148 was decreased in diabetic subjects. Addition-
ally, the peak intensity of the m/z value of 27,714 was
decreased in CD4+ T-cells of diabetic subjects, and
the peak intensity of the m/z value of 27,741 was also
decreased in muscle tissues of diabetic subjects. Fur-
ther mass spectrometric studies need to be done to
identify these proteins.
Relationship of transcriptomes in cellu-
lar function
Forty-four genes that were altered in expression be-
tween normal and diabetic subjects were analyzed by
Ingenuity software using GOs and KEGG (Kyoto En-
cyclopedia of Genes and Genomes) pathways. Table 7
shows the biological profiling of these 44 genes (bold),
which are clustered into 3 groups with integration of
their functional pathways, together with other genes
(non-bold) that are also involved in these pathways.
In Group I, 17 of these genes (bold), such as INSR and
insulin receptor substrate-1 (IRS-1), are linked with
other genes (non-bold) with the main function of car-
bohydrate metabolism and cell signaling. In Group
II, another 13 genes that were altered in expression
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Fig. 5 A and B. The 2D gel profiles of activated CD4+ T-cells of diabetic and normal subjects, respectively, with pI
ranging from 3 to 10 for the first dimension. C. Analysis of the above activated CD4+ T-cells of diabetic and normal
subjects using the Beckman Coulter ProteomeLab PF 2D Protein Fractional System by isoelectric focusing and reverse
phase separation of proteins. D. The protein peaks were compared between diabetic (red) and normal (green) subjects.
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Fig. 6 A. SELDI-TOF MS profiles of muscle tissues and CD4+ and CD8+ T-cells of normal and diabetic subjects in
the m/z range of 100–30,000. B. SELDI-TOF MS profiles of CD4+ T-cells of normal and diabetic subjects in the m/z
range of 30,000–150,000.
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Table 6 Potential biomarkers for diabetes in CD4+ T-cells and muscle tissues
Normal Diabetic
CD4+ (m/z) Muscle (m/z) CD4+ (m/z) Muscle (m/z)
3,459 3,366 – 3,366
3,903 3,903 3,433 –
4,154 3,481 4,154 3,481
5,979 3,881 5,979 3,881
6,650 6,654 6,650 6,654
7,760 7,771 7,760 –
8,769 8,786 8,760 8,786
9,276 9,295 9,276 –
10,617 – 10,617 –
10,846 10,845 – 10,845
11,714 11,732 11,714 –
13,210 – 13,210 –
– – 15,642 15,642
– – 16,721 16,721
– – 17,356 17,356
21,148 21,148 21,148 21,148
22,356 22,356 23,467 23,467
27,714 27,741 27,714 27,741
110,000 110,000 110,000 110,000
119,700 119,700 119,700 119,700
Table 7 Ingenuity biological profiling of genes altered in expression in diabetic subjects
Genes Focus genes Top functions
INSR, IRS1, IRS2, IRS4, PEPCK, IL2, GAPD,
PDK1, PDK2, PFK, IL2RB, IGF1R, ENPP1,
Foxo1, GLUT4, JAK1, VDR, AHSG, ATP2A3,
CAV3, CD276, CX3CR1, FER (tyrosine kinase), IFNG,
IL2RA, MICA, NCR1, NISCH, PAEP, PDCD1, PD-
CDILG2, PDE4B, PHIP, SLC2A4, TXX, VTCN1
17 Carbohydrate metabolism,
molecular transport,
small molecule biochemistry,
cell signaling
AKT3, CALM2, G6PD, HK3, IPF1, LDHA,
LDHB, PDE1C, PDHB, PDHE, PDK4, PIP5K3,
FBP, CART, CNN2, CTNNB1, Cyp2d10, DLAT,
DLD, GNPAT, GPAM, INS1, KCNJ1, LEP, LTC45,
MAFA, MF12, OAT, PDE3B, PDHA1, PDHA2, PL53,
PRKAA1, TAXIBP3, TGFB1
13 Carbohydrate metabolism,
small molecule biochemistry,
lipid metabolism
CALM1, H6PD, HK1, HK2, IDE, INSIG1,
CAT, LDHC, PDE1A, PDE1C, PKM2, SP1,
TNFα, TNFR, AEBP1, CCRN4L, CD18, CD1C, CLA,
CTLA2A, EPHB4, GPAM, HGF, HRSP12, ICOSLG,
IFI203, IFIT3, IL4, KITLG, LTC45, MAT2A, MTPN,
NFIX, RNF128, SLC29A1
14 Hepatic system,
cardiovascular system devel-
opment and function,
cell-to-cell signaling and in-
teraction
are grouped and linked with genes involved in car-
bohydrate and lipid metabolism. The other 14 genes
are linked in the third group with genes involved in
the hepatic and cardiovascular systems and cell-to-cell
signaling. Figure 7 shows the merging of these path-
ways to integrate the interaction of different pathways
of the three groups of these genes and their relation-
ship with other genes that are also involved in these
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Fig. 7 The merged pathway interactions using Ingenuity software of some of the genes found to be altered between
normal and diabetic subjects and the interactions of other genes involved with these pathways.
pathways. This demonstrates the relationship be-
tween certain enzymes of intracellular pathways that
are affected in T-cells and muscle tissues, and shows
the complexity of the relationship between the genes
expressed and their far reaching effect on other parts
of the system. It also indicates that the alteration in
expression of these genes in diabetic subjects can lead
to the alteration of numerous pathways and physio-
logical processes involved in T2DM.
Discussion
Our results indicate the expansive effect of elevated
glucose in the disease state of T2DM on gene expres-
sion with the main focus on carbohydrate metabolism
and insulin signaling along with the relationship with
inflammation. Based on many studies, the insulin
binding to its receptor in insulin-sensitive tissues re-
sults in activation of multiple IRSs and numerous en-
zymes involved in insulin signal transduction (12–15,
19–25 ). Using the human genome microarrays, we
have demonstrated the relationship of numerous genes
that were increased or decreased in T2DM.
In this study, the transcriptome for INSR was de-
creased in diabetic subjects compared with that of
normal subjects, so were the transcriptomes for IRS-
1 and IRS-2 (Figure 2). Although our 2D-PAGE, PF
2D, and MS anlayses for the translation of the pro-
teome were inconclusive, the SELDI-TOF MS profile
(Figure 6) showed peaks in the range of the molecu-
lar weights (MWs) of IRS-1 (131,591 Da) and IRS-2
(137,334 Da). We have previously shown that the
activation of T-cells with high glucose or saturated
fatty (palmitic) acids activates the de novo expression
of INSR on the cell surface of T-cells (4, 9, 11, 26 )
and increases IRS-1 and IRS-2 (5, 11, 26 ). However,
these expressions were decreased in diabetic subjects
(9 ). Such a decrease of IRS-1 and IRS-2 in diabetic
subjects would impair insulin signaling, glucose trans-
port and metabolism, lipid metabolism, and protein
synthesis.
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IDE has been shown to be an important enzyme
involved in insulin sensitivity (27–31 ). Our results
demonstrated that the IDE transcriptome in muscle
tissues and activated CD4+ and CD8+ T-cells was de-
creased in expression in diabetic subjects. Mass spec-
trometric characterization of proteins on the SELDI-
TOF MS data indicated a protein (proteins) with an
m/z value of 119,700, which is approximate to the
MW of IDE. The peak intensity was decreased in
diabetic subjects, which correlates with our earlier
findings (27 ).
Central within the insulin signaling cascades are
many protein kinases. One of these activated protein
kinases is Akt (also known as protein kinase B). Acti-
vated Akt has many targets, including glucose trans-
port pathways, potassium transport pathways, and
protein metabolism. Another major protein kinase is
p38 MAPK. The targets of p38 MAPK are less well-
established, but are thought to also include glucose
transport pathways, potassium transport pathways,
and protein metabolism. Although both human and
animal studies indicate that the Akt and p38 MAPK
pathways are affected in T2DM, the specific role that
hyperglycemia has on signal transduction by these
pathways is not known (18, 32, 33 ). Our results pre-
sented here corroborate these findings by demonstrat-
ing particular differences in gene expression between
diabetic and non-diabetic subjects in insulin signal
transduction genes, such as Akt3 and IRS-1, as well
as in the emergence of growth factor receptors (INSR,
IGF-1R, and IL-2R). Additionally, the differences in
the MW range of Akt3 (54,032 Da) in the SELDI-
TOF MS profile were observed. These findings in
CD4+ or CD8+ T-cells are parallel to those in muscle
tissues with respect to many of the transcriptomes
and proteomes, indicating that these tissues behave
similarly in normal or diabetic subjects and could be
used interchangeably for T2DM studies since T-cells
are more readily accessible than muscle tissues.
This study further extends the findings in muscle
tissues of diabetic and normal subjects by comparing
microarray data of genomic and proteomic expression
in both T-cells and muscle tissues. Activated CD4+
and CD8+ T-cells, analogous to muscle cells, express
insulin signaling and glucose metabolism genes and
gene products. Muscle tissues and activated T-cells
of diabetic subjects exhibit less than half of the ex-
pression of genes and gene products in numerous path-
ways compared with those of normal subjects. One
of our interesting findings is that the gene expression
of ENPP-1, a membrane protein that has been shown
to be increased in diabetes and insulin resistance by
Maddux and Goldfine (34 ), was increased in T-cells
and muscle tissues of diabetic subjects to be at least
two folds of that in normal subjects. Extending these
genomic studies to the proteome level with MS anal-
ysis revealed a protein of 110,000 m/z, which was in-
creased in diabetic subjects within the MW range of
the ENPP-1 protein. Therefore, we propose that some
transcriptome and proteome changes may be involved
in the insulin resistance of diabetic subjects relative
to normal subjects.
The hierarchial clustering heat map classifies some
of the genes altered in expression between normal
and diabetic subjects into insulin signal transduction,
carbohydrate metabolism, and inflammation. The
inflammatory genes of TNFα, TNFα receptor, and
NFKB1 were increased in expression in diabetic sub-
jects, supporting the concept that inflammation is
linked to insulin resistance. Although TNFα was
much more expressed in T-cells than in muscle tis-
sues, it showed a similar relationship of increase in
both T-cells and muscle tissues in diabetic subjects.
SELDI-TOF MS showed differences in peaks in the
MW range of TNFα and TNFα receptor (17,270 Da
and 35,478 Da), respectively, with increase in dia-
betic subjects. These levels correlate with the previ-
ous studies that have shown increased blood levels of
TNFα in diabetic subjects (10 , 35 ) and other studies
with diabetic animals (36 ).
The T-cell growth factor IL-2 and IL-2R were de-
creased in expression in T-cells of diabetic subjects,
whereas neither was present in muscle tissues of nor-
mal or diabetic subjects. SELDI-TOF MS showed
differences in peaks in the MW range of IL-2 and
IL-2R (17,628 Da and 30,819 Da), respectively, with
decreased peak heights in T-cells of diabetic subjects
while none was observed in muscle tissues, as we have
reported in our flow cytometry and tissue immuno-
hystochemistry studies (5 , 8 , 11 ).
Our results showed that the VDR gene expression
was decreased in diabetic subjects. SELDI-TOF MS
showed differences in peak heights in the MW range of
VDR (48,289 Da) between diabetic and normal sub-
jects. VDR has been shown to be an important anti-
inflammatory agent (37 , 38 ), therefore, it may have
important implications in the increased infections in
diabetic subjects.
The diabetic state is associated with increased
gluconeogenesis. Our results showed that two of the
rate-limiting enzymes of gluconeogenesis, FBP and
PEPCK, as well as the ketogenic enzyme and CAT,
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were increased in expression in T-cells and muscle tis-
sues of diabetic subjects. SELDI-TOF MS showed
differences in peak heights in the MW range of FBP,
PEPCK, and CAT (37,188 Da, 69,195 Da, and 70,926
Da), respecptively. The increase of these enzymes
would result in an increase of blood glucose and ketone
levels in diabetic subjects. The gene expression of the
transcription factor Foxo1, which is involved in carbo-
hydrate metabolism, was also increased in T-cells and
muscle tissues of diabetic subjects. SELDI-TOF MS
showed differences in peak heights in the MW range
of Foxo1 (69,662 Da). These findings corroborate the
findings of increased Foxo1 in diabetes by Nakae et al
(39 ).
These transcriptome and proteome expression re-
sults seem to corroborate a number of the proteomic
results that have been observed by immunoassay, flow
cytometry, and immuno blotting in our previous stud-
ies. However, due to the fact that SELDI-TOF MS
does not specifically identify a protein but only make
a comparison of the MS profile over the m/z range,
further 2D separation electrophoresis and MALDI-
TOF MS studies are needed for identification of each
protein.
For the 23 picked transcriptomes that were found
to be altered between normal and diabetic sub-
jects, quantitative RT-PCR confirmed the directional
changes of these transcriptomes observed from mi-
croarray data, suggesting that microarray data are
reliable to express the relationship of gene expression
between normal and diabetic subjects.
The microarray data showed decreased expres-
sion of INSR and GLUT4 and increased expression
of TNFα in diabetic subjects. When gene silenc-
ing was used to study the effect of the silencing of
INSR on the glucose transport by determining the
expression of GLUT4, we found that decreasing the
expression of INSR also resulted in a decrease in the
GLUT4 expression. However, decreasing the expres-
sion of TNFα by gene silencing resulted in an increase
in the GLUT4 expression. Thus, this demonstrates
the effect of INSR and TNFα on regulating glucose
transport and metabolism, as well as the effect of the
expression of one gene on the expression of another
as shown in Figure 7. When these transcriptomes
along with other transcriptomes (Table 7) were ana-
lyzed by Ingenuity software, they were shown to be
also involved in the hepatic and cardiovascular sys-
tems as well as carbohydrate and cell signaling sys-
tems. When the genes of these functions were merged
(Figure 7), the intricate relationship can be seen be-
tween a gene expression and how it could affect other
genes involved in these functions.
It has been shown that activated T-cells along with
activated human aortic endothelial cells (HAECs)
play a pivotal role in the development of athrogenic
plaques (40 , 41 ). We have recently shown that glu-
cose or palmitic acids can activate both HAECs and
T-cells with production of ROS, lipid peroxidation,
and generation of proinflammatory cytokines and in-
sulin signal transduction intermediates (11, 26, 42 ).
The elevated glucose and palmitic acids as occurred in
T2DM on T-cell activation play an important role in
the athrogenic plaque formation; therefore, inhibition
of the activation through part of the signal transduc-
tion mechanism could prevent the T-cell activation
and plaque formation.
Our present study used PHA to activate T-cells
and study the patterns of genomic and proteomic ex-
pressions, and we assume that similar patterns would
be observed when these cells are activated with glu-
cose or palmitic acids, as would be encountered in in
vivo conditions. However, we cannot state with cer-
tainty the exact pattern of changes in genomic and
proteomic expressions under such in vivo conditions,
but such studies are needed for verification of the
changes between diabetic and non-diabetic subjects.
Additionally, our studies were performed on diabetic
and non-diabetic African American subjects. Since
there are significant phenotypic differences between
African American and Caucasian subjects, these stud-
ies need to be further verified on Caucasian subjects.
Conclusion
We conclude that there are significant differences in
genomic and proteomic patterns of activated T-cells
between diabetic and non-diabetic subjects, and these
findings parallel our in situ findings in muscle tis-
sues of diabetic and non-diabetic subjects. Further
studies should be conducted using T-cells, which are
more readily available than muscle. Besides, T-cells
are important in that they are intricately involved
in the immune system and inflammation, and also
play a pivotal role in plaque formation and cardio-
vascular disease, which is a major complication of
T2DM (40 ). Although the diabetic subjects in this
study were newly diagnosed and has not yet developed
currently observable complication of diabetes such as
retinopathy, nephropathy, and neuropathy, the alter-
ations in the transcriptome and proteome expressions
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in CD4+ and CD8+ T-cells and muscle tissues of dia-
betic subjects compared with those in normal subjects
demonstrate that tissue changes were already occur-
ring. These and additional studies could help delin-
eate biomarkers to identify subjects who may have
T2DM and lead to the development of therapeutic
interventions targeting such affected genes and pre-
venting complications due to diabetes.
Materials and Methods
Subject selection
Five male subjects with newly diagnosed T2DM and
five non-diabetic controls were selected for the study,
who were matched for BMI (28–40), age (30–56), and
ethnicity (African American). They had no history of
systemic or metabolic diseases and were on no medi-
cations. The diabetic subjects had normal chemistry
profiles except high glucoses and were free of microan-
giopathy, and had no history of macrovascular dis-
eases or other complications associated with T2DM.
These subjects were enrolled into the study after sign-
ing the consent form approved by the University of
Tennessee Health Science Center institutional review
board. Assessment of glycemic control was done by a
2-hour OGTT of 75 g dextrose ingestion after 3 days
of high carbohydrate diet according to the American
Diabetes Association (ADA) criteria (43 ). All sub-
jects had normal complete blood count (normal range
of white blood cells) with no indication of infection or
inflammation.
Sample collection and laboratory pro-
cessing
Blood samples (70 mL) of the studied subjects were
obtained in EDTA from an antecubital vein after an
overnight fast. The plasma was used for hormone
and metabolite measurements. The buffy coat was
used for isolation of the peripheral blood leukocytes
(PBLs). Muscle biopsies were obtained from the vas-
tus lateralis muscle (thigh muscle). Following local
anesthesia (mepivacaine chloride 5 mg/mL), a 5-mm
incision in the skin and muscle fascia allowed for 100–
200 mg muscle biopsy to be obtained with a Weil-
Blakesley conchotome. Each biopsy was immediately
placed in 1 mL of TRIZOL reagent (Invitrogen, Carls-
bad, USA) and was homogenized (8 ).
Isolation of CD4+ and CD8+ T-cells
PBLs were isolated by centrifugation of 70 mL of
whole blood at 500×g for 10 min. The upper layer
of plasma was removed. The buffy coat was then
removed, diluted to 30 mL with phosphate buffered
saline (PBS; 0.1% human serum albumin, pH 7.4),
layered over Ficoll-Hypaque, and centrifuged. The
band of PBLs was then washed with PBS. The CD4+
and CD8+ T-cells were isolated from the PBLs by
negative selection using the CD4 and CD8 lympho-
cyte negative isolation reagents (Dynal Biotech ASA,
Oslo, Norway), respectively (4 , 5 ).
Activation of T-cells
The isolated CD4+ and CD8+ T-cells were counted
on a Coulter ACT diff hematology analyzer (Beck-
man Coulter, Miami, USA) and diluted to 10 × 106
cells per mL. One mL (10 × 106) of cells was incu-
bated in a 25-mL tissue culture flask in RPMI 1640
medium containing 90 mg/dL glucose with no PHA
(non-activation), and another one mL of cells was in-
cubated for the same time period in another flask with
1 ng/mL PHA (for activation). The cells were main-
tained in 5% CO2 and 95% air and incubated for 72
h, then the cells (10 × 106) were placed in TRIZOL
for RNA and protein extraction. According to the
de novo emergence of gene expression of the insulin
and other growth factor receptors and insulin signal-
ing genes upon activation in normal CD4+ and CD8+
T-cells from normal individuals in our previous stud-
ies (8 ), we used the activated CD4+ and CD8+ T-cells
for this study.
Isolation of RNA and proteins from T-
cells and muscle tissues
Chloroform (0.2 mL) was added to the tubes contain-
ing T-cells (CD4+ or CD8+) or muscle tissues that
had been placed in TRIZOL. The RNA and proteins
were isolated as previously described (44 , 45 ). RNA
from each individual time point of each subject was
probed with a microarray chip (8 ).
cRNA synthesis and labeling
The first and the second strand of cDNA were syn-
thesized from 5–15 µg of total RNA using the Super-
Script Double-Stranded cDNA Synthesis Kit (Gibco
Life Technologies, Rockville, USA) and oligo-dT24-T7
(5′-GGCCAGTGAATTGTAATACGACTCACTATA
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GGGAGGCGG-3′) primer according to the manu-
facturer’s instructions. cRNA was synthesized and
labeled with biotinylated UTP and CTP by in vitro
transcription using the T7 promoter-coupled double-
stranded cDNA as template and the T7 RNA Tran-
script Labeling Kit (ENZO Diagnostics Inc., Farm-
ingdale, USA). The labeled cRNA was separated from
unincorporated ribonucleotides by passing through a
CHROMA SPIN-100 column (Clontech, Mountain
View, USA) and precipitated at −20◦C from 1 h to
overnight as previously described (8 ).
Oligonucleotide array hybridization and
analysis
The cRNA pellet was fragmented and hybridized to
HG U133A Plus 2 oligonucleotide arrays (Affymetrix,
Santa Clara, USA) containing in excess of 400,000
full-length annotated nucleotide sequences to permit
the simultaneous detection and quantitation of 31,000
human genes with additional probe sets designed to
represent EST sequences for simultaneous detection
and quantitation on one array. The arrays were
then stained with phycoerythrein conjugated strepta-
vidin (Molecular Probes Inc., Eugene, USA) and the
fluorescence intensities were determined using a laser
confocal scanner (Hewlett-Packard, Palo Alto, USA).
The scanned images were analyzed using microarray
software (Affymetrix). Sample loading and variations
in staining were standardized by scaling the average
of the fluorescent intensities of all genes on one array
to constant target intensity (250) for all arrays used,
all as we have previously described (8 ).
Quantitative RT-PCR analysis
The RNA extracted from the cells for gene expres-
sion analysis by the Affymetrix microarrays was an-
alyzed by RT-PCR to quantitate the amount of mR-
NAs transcribed for the various genes to confirm the
information from the microarrays. Reverse transcrip-
tion of 250 ng of total RNA was performed using 125
U Multiscribe reverse transcriptase (Applied Biosys-
tems, Foster City, USA). The cDNA was then an-
alyzed by Applied Biosystems TaqMan low density
arrays with 24 sets of genes. Each reaction con-
sisted of 0.5–1 ng of cDNA per well in a final vol-
ume of 1 µL. Primer/probe sets were chosen from the
pre-designed TaqMan gene expression assays. The
cDNA was mixed with 2× TaqMan Universal Mas-
termix and 100 µL of the mixture was loaded into
each filling port. The plates were then centrifuged
to distribute the mixture into the wells. Quantita-
tive RT-PCR was performed on an Applied Biosys-
tems 7900HT system. Absolute threshold cycle val-
ues (Ct values) were determined using SDS soft-
ware (Applied Biosystems). The Ct values of the
23 mRNAs were normalized against the mean Ct
value of the 18S rRNA (∆Cttest gene = Cttest gene −
mean Ct18S). The ∆Cttest gene of normal subjects
was then subtracted from the ∆Cttest gene of dia-
betic subjects (∆∆Cttest gene = ∆Cttest gene diabetic−
∆Cttest gene normal). The larger the ∆∆Cttest gene,
the less the amount of mRNAs in diabetic subject
cells (46 ).
Gene silencing to delineate gene func-
tion
RNAi was used for gene knockout to study the effect
of decreases in mRNA expression levels. The CD4+
T-cells of normal subjects were transfected with Am-
bion’s Silencer siRNAs (Ambion, Austin, USA) be-
fore activation of the cells, and mRNA knockout lev-
els were measured using the same method as de-
scribed above. An amount of 1 nM and 10 nM con-
centrations of Ambion’s Silencer validated siRNAs
for INSR (ID No. 31, 29, and 103467; RefSeq Ac-
cession NM 000208) or TNFα pre-designed siRNAs
(ID No. 138754, 1338753, and 138752; RefSeq Ac-
cession NM 000594) was transfected into the T-cells
prior to activation, respectively. The levels of mRNA
for INSR, TNFα, and GLUT4 were assessed using
RT-PCR with pre-designed TaqMan gene expression
assays for INSR (NM 000208), TNFα (NM 000594),
and GLUT4 (NM 001042), respectively. 18S rRNA
was used to normalize from sample to sample. The
percent relative gene expression to the control (no
siRNA added) was determined (47 ).
Proteins translated
Proteins from muscle tissues and activated and non-
activated CD4+ and CD8+ T-cells of normal and dia-
betic subjects were extracted using TRIZOL reagent
according to the manufacturer’s recommendations,
and were then analyzed by 2D-PAGE and the Ci-
phergen PBSII SELDI-TOF MS System (Ciphergen
Biosystems, Fremont, USA) (8 ).
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2D-PAGE
Prior to 2D-PAGE separation, the proteins from the
CD4+ and CD8+ T-cells and muscle tissues of normal
and diabetic subjects extracted from TRIZOL reagent
were solubilized in a standard rehydration solution
containing urea, thiourea, dithiothreitol, CHAPS de-
tergent, ampholytes, and protease/phosphatase in-
hibitors. Protein concentration in the rehydration
buffer was determined by the 2-D Quant Kit (Amer-
sham Biosciences, Piscataway, USA).
In the first dimension of 2D-PAGE, the proteins
were subjected to isoelectric focusing (IEF), which
separated the proteins according to their isoelectric
points (pI). In the second dimension of 2D-PAGE,
the proteins were separated by sodium dodecyl sul-
fate (SDS)-PAGE according to their MWs. A Multi-
phor II apparatus (Amersham) for IEF and a Protean
Dodeca Plus apparatus (Bio-Rad, Hercules, USA) for
SDS-PAGE were used in this study as previously de-
scribled (48 , 49 ).
For IEF of the protein mixtures, pre-cast gel strips
with immobilized pH gradients were used (18 cm, pH
3–10). The total protein load was 100–200 µg. For
the second dimension of 2D-PAGE, self-cast polyacry-
lamide gels of 20×20 cm was used. After SDS-PAGE,
the proteins in the 2D gels were visualized using the
SYPRO Ruby fluorescence since it has a dynamic
range of 1–10 ng and has an end-point reaction. The
FX Molecular Imager (Bio-Rad) was used to scan the
gels and create digitized images for computer-assisted
spot pattern analysis, and the gel images were saved
in an Adobe Photoshop format.
PF 2D system
The liquid-based 2D protein separation technology,
the ProteomeLab PF 2D Protein Fractional System
(Beckman Coulter, Fullerton, USA) for proteome
analysis, was also used in this study because of the
complex differences observed in the samples by 2D
gels and the number of samples to be analyzed (50 ).
The PF 2D system separated the proteins in com-
plex mixtures in the first dimension using high perfor-
mance chromatofocusing according to their pI, then
automatically generated a sequence table for auto-
mated injection of the fractions into the second di-
mension where separation occurred according to hy-
drophobicity. Fractions were collected from the sec-
ond dimension into a 96-well plate for analyses of the
peaks by MS. The software allowed for comparison of
peaks of different samples, therefore the differences
of protein peaks between samples were determined.
This system could accommodate up to 5-mg protein,
which allows for detection of proteins in lower concen-
trations.
MS analysis
MS analysis of the proteomes was performed using
the Ciphergen PBSII SELDI-TOF MS System on
gold (AU), hydrophobic (H50), anion exchange (Q10),
and cation exchange (CM10) chip arrays (Ciphergen
Biosystems). Differences between the cellular pro-
teins of muscle tissues and activated CD4+ and CD8+
T-cells of normal and diabetic subjects were deter-
mined using Ciphergen MS software (8 , 51 ).
Protein digestion for MALDI-TOF MS
The protein peaks collected in the wells of the 96-
well plates were proteolytically digested to produce
a mixture of peptides. Trypsin was used as the
first choice, or if needed, proteases with different
specificities, such as endoprotease Lys-C or Glu-C,
were employed. The protein digests were extracted
with a C18 minicolumn and were then analyzed on
the MALDI-TOF mass spectrometer (Thermo Finni-
gan, San Jose, USA) (52 ).
Data analysis for gene expression
Data analysis was conducted using GeneChip operat-
ing software (Affymetrix) and GeneSifter (VizX Labs
LLC, Seattle, USA) software following user guide-
lines. The signal intensity for each gene was calcu-
lated as the average intensity difference, represented
by [Σ(PM − MM)/(the number of probe pairs)],
where PM and MM denote perfect match and mis-
match probes, respecitively. To identify genes that
are differentially expressed in T-cells between newly
diagnosed T2DM subjects and normal subjects, the
following filtering method was used. Affymetrix de-
tection calls were used to remove genes that did not
have all “Present” calls for each sample in at least one
group. Genes that met these criteria and showed at
least a 1.5-fold change between any of the groups were
then subjected to the analysis of variance (ANOVA).
Raw p-values from ANOVA were adjusted using the
method of Benjamini and Hochberg (53 ) to calculate
a false discovery rate. A false discovery rate of less
than or equal to 1% was then applied to generate
a list of differentially expressed genes. Hierarchical
232 Geno. Prot. Bioinfo. Vol. 5 No. 3–4 2007
Stentz and Kitabchi
clustering was used to visualize the filtered gene list
and identify patterns of gene expression. K-medoids
clustering was used to partition the filtered gene list
based on expression pattern. Clusters showing gene
expression patterns of interest were then examined
on a gene-by-gene basis using the annotation from
UniGene and Entrez Gene databases. Additionally,
z-score analysis (54 ) was used for the GO and KEGG
pathway terms associated with the genes in the cluster
to identify biological themes associated with a cluster
of interest. As our main focus of pathways was on
insulin receptor, insulin signaling, glucose transport,
glucose and lipid metabolism, and immune function
pathways, we specifically analyzed these pathways in
this study using Ingenuity software.
SELDI-TOF MS
Ciphergen ProteinChip 3.1 software was used to cal-
culate and subtract the background, and Biomarker
Wizard software was used to detect peaks with a sig-
nal to noise ratio of 5 or greater, to match peaks
within a mass window of 0.3%, and to perform sta-
tistical analysis using a t-test to determine significant
differences in protein expression. Data were exported
to Statview 5.0 software to perform ANOVA and eval-
uate the significance of multiple comparisons. These
analyses defined the patterns of protein expression
that consistently differed in muscle tissues and acti-
vated CD4+ and CD8+ T-cells between normal and
diabetic subjects (8 ).
2D-PAGE image analysis
The TIFF images of the scanned gels were imported
into PDQuest image analysis software (version 7.1,
Bio-Rad), which allows the intensities of protein spots
in many gels to be compared at once when compos-
ite gels are created, and advanced statistical analyses
were performed. The protein spots were detected us-
ing the automated spot detection feature, and the cor-
rection for undetected or incorrectly detected spots or
artifacts was done by visual inspection using a strin-
gent definition of spots in order to avoid collecting
data from very faint spots that tend to have substan-
tial intersample variability and reproducibility. The
spot intensity (the integration of optical density over
the spot’s area) was determined, and differential data
analysis was performed to quantify spot variations
from gel to gel. Statistical analysis, using univariate
and multivariate statistical techniques, was performed
on the groups of proteins from normal and diabetic
subjects to determine the differences in protein ex-
pression between the two kinds of subjects (48 , 49 ).
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